Similar Search Results

Pricing in the market for anticancer drugs

Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - In: The journal of economic perspectives : EP ; a journal … 29 (2015) 1, pp. 139-162

Persistent link: https://www.econbiz.de/10011409439

Specialty drug prices and utilization after loss of us patent exclusivity, 2001-2007

Conti, Rena M.; Berndt, Ernst R. - In: Measuring and modeling health care costs, (pp. 273-321). 2018

Persistent link: https://www.econbiz.de/10011812702

Pricing in the market for anticancer drugs

Howard, David H.; Bach, Peter B.; Berndt, Ernst R.; … - 2015

Persistent link: https://www.econbiz.de/10010485559

Specialty drug prices and utilization after loss of US patent exclusivity, 2001 - 2007

Conti, Rena M.; Berndt, Ernst R. - 2014

Persistent link: https://www.econbiz.de/10010352001

How do initial signals of quality influence the diffusion of new medical products? : the case of new cancer drug treatments

Conti, Rena M.; Bernstein, Arielle; Meltzer, David - In: The economics of medical technology, (pp. 123-148). 2012

Persistent link: https://www.econbiz.de/10010212752

Pricing in the Market for Anticancer Drugs

Howard, David H. - 2015

Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch...

Persistent link: https://www.econbiz.de/10012457799

Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007

Conti, Rena M. - 2014

2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally …

Persistent link: https://www.econbiz.de/10012458648